Cambridge Heart has signed an agreement with EO Medical for distributing HearTwave II System, Microvolt T-Wave Alternans (MTWA) software and Micro-V Alternans Sensors in Singapore following regulatory approval.

MTWA is a marker of Sudden Cardiac Arrest (SCA) risk which is measured during a non-invasive treadmill test using Cambridge Heart’s proprietary technologies.

Cambridge Heart CEO Ali Haghighi-Mood said they look forward to gaining regulatory approval in Singapore, which they expect will occur within the next six to nine months, and begin marketing their MTWA technology.